Cerus/$CERS
1D1W1MYTD1Y5YMAX
Capital at risk
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
- Ticker
- $CERS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 268
- Headquarters
- Concord, United States
- Website
- www.cerus.com
Cerus Metrics
BasicAdvanced
$534M
-
-$0.03
1.80
-
Price and volume
Market cap
$534M
Beta
1.8
52-week high
$3.47
52-week low
$1.31
Average daily volume
1.9M
Financial strength
Current ratio
1.834
Quick ratio
1.017
Long term debt to equity
0.615
Total debt to equity
1.086
Interest coverage (TTM)
-0.21%
Profitability
EBITDA (TTM)
0.066
Gross margin (TTM)
52.05%
Net profit margin (TTM)
-3.06%
Operating margin (TTM)
-0.73%
Effective tax rate (TTM)
-6.05%
Revenue per employee (TTM)
$830,000
Management effectiveness
Return on assets (TTM)
-0.48%
Return on equity (TTM)
-10.77%
Valuation
Price to revenue (TTM)
2.329
Price to book
7.62
Price to tangible book (TTM)
7.77
Price to free cash flow (TTM)
-282.095
Free cash flow yield (TTM)
-0.35%
Free cash flow per share (TTM)
-0.009
Growth
Revenue change (TTM)
15.09%
Earnings per share change (TTM)
-65.42%
3-year revenue growth (CAGR)
13.03%
10-year revenue growth (CAGR)
20.41%
3-year earnings per share growth (CAGR)
-50.42%
10-year earnings per share growth (CAGR)
-25.51%
What the Analysts think about Cerus
Analyst ratings (Buy, Hold, Sell) for Cerus stock.
Analyst projections of the future price of Cerus stock.
Bulls say / Bears say
: Product revenue grew 10% year-over-year to $57.4 million in Q2 2026, driven by strength in both the core INTERCEPT platelet franchise and the U.S. IFC business, surpassing the $62.9 million revenue forecast. (Reuters)
: Full-year 2026 product revenue guidance was raised to $229 million–$231 million, implying 11%–12% growth and demonstrating management’s confidence in sustained sales momentum. (Reuters)
: Adjusted EBITDA of $3 million marked the ninth consecutive quarter of positive non-GAAP earnings, underlining accelerating operational leverage toward profitability. (Reuters)
: GAAP net loss of $2.9 million (–$0.01 per share) in Q2 2026 underscores the company’s persistent bottom-line unprofitability despite revenue growth. (Reuters)
: Gross margin contracted to 51.4%, down from 55.2% a year earlier, reflecting FX and inflation headwinds that pressure profitability. (Reuters)
: Operating cash outflow totaled $2.7 million in Q2 2026, indicating ongoing cash burn and potential liquidity strain as the company invests ahead of full GAAP profitability. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Cerus Financial Performance
Revenues and expenses
Cerus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cerus News
AllArticlesVideos
Funds containing Cerus
Fund name | Fund size | $CERS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.